2023
DOI: 10.1016/j.jhep.2023.06.003
|View full text |Cite
|
Sign up to set email alerts
|

A multisociety Delphi consensus statement on new fatty liver disease nomenclature

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

3
278
0
2

Year Published

2023
2023
2024
2024

Publication Types

Select...
5
1

Relationship

1
5

Authors

Journals

citations
Cited by 942 publications
(476 citation statements)
references
References 32 publications
3
278
0
2
Order By: Relevance
“…Because the data are deidentified and publicly accessible, no additional review board approval was required (eMethods in Supplement 1). SLD was defined as ultrasonography-confirmed hepatic steatosis . An intermediate or high risk for advanced fibrosis was defined by a Fibrosis-4 index (FIB-4) score of 1.3 or higher.…”
Section: Methodssupporting
confidence: 88%
See 1 more Smart Citation
“…Because the data are deidentified and publicly accessible, no additional review board approval was required (eMethods in Supplement 1). SLD was defined as ultrasonography-confirmed hepatic steatosis . An intermediate or high risk for advanced fibrosis was defined by a Fibrosis-4 index (FIB-4) score of 1.3 or higher.…”
Section: Methodssupporting
confidence: 88%
“…Alcohol exacerbates liver disease progression, leading to advanced fibrosis and cirrhosis. A recent update in nomenclature, steatotic liver disease (SLD), encompasses all fatty liver diseases confirmed by histological or radiological evidence, irrespective of etiology …”
Section: Introductionmentioning
confidence: 99%
“…Several large international liver disease societies recommended changing the nosology of fatty liver disease to steatotic liver disease (SLD), with subcategories of metabolic dysfunction–associated steatotic liver disease (MASLD), alcohol liver disease (ALD), and the combination of MASLD and ALD as “MetALD.” The impact of this shift will need to be evaluated in subsequent studies and reflected in updated guidelines. Upcoming data from larger RCTs of GLP1RAs, GIPRAs/GLP1RAs, and sodium-glucose cotransporter 2 inhibitors should help clarify their direct effects on NASH.…”
Section: Areas In Need Of Future Study or Ongoing Researchmentioning
confidence: 99%
“…The renaming comes after a two year process led by the American Association for Study of Liver Disease and EASL in collaboration with the Asociación Latinoamericana para el Estudio del Hígado. Details of the renaming will be published in the Journal of Hepatology 1…”
mentioning
confidence: 99%
“…British experts and authors for the Journal of Hepatology report come from Oxford, Southampton, Newcastle, and Birmingham 1…”
mentioning
confidence: 99%